Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7

Mohammed I Hawa, Hubert Kolb, Nanette Schloot, Huriya Beyan, Stavroula A Paschou, Raffaella Buzzetti, Didac Mauricio, Alberto De Leiva, Knud Yderstraede, Henning Beck-Neilsen, Jaakko Tuomilehto, Cinzia Sarti, Charles Thivolet, David Hadden, Steven Hunter, Guntram Schernthaner, Werner A Scherbaum, Rhys Williams, Sinead Brophy, Paolo Pozzilli, Richard David Leslie, Action LADA consortium, R D L, M I H, H B, S A P, P P, R W, S B, H B-N, K Y, S H, D H, R B, W A S, H K, N S, J Seissler, G S, J T, C S, A D L, E Brugue, D M, C T, Mohammed I Hawa, Hubert Kolb, Nanette Schloot, Huriya Beyan, Stavroula A Paschou, Raffaella Buzzetti, Didac Mauricio, Alberto De Leiva, Knud Yderstraede, Henning Beck-Neilsen, Jaakko Tuomilehto, Cinzia Sarti, Charles Thivolet, David Hadden, Steven Hunter, Guntram Schernthaner, Werner A Scherbaum, Rhys Williams, Sinead Brophy, Paolo Pozzilli, Richard David Leslie, Action LADA consortium, R D L, M I H, H B, S A P, P P, R W, S B, H B-N, K Y, S H, D H, R B, W A S, H K, N S, J Seissler, G S, J T, C S, A D L, E Brugue, D M, C T

Abstract

Objective: Specific autoantibodies characterize type 1 diabetes in childhood but are also found in adult-onset diabetes, even when initially non-insulin requiring, e.g., with latent autoimmune diabetes (LADA). We aimed to characterize adult-onset autoimmune diabetes.

Research design and methods: We consecutively studied 6,156 European diabetic patients attending clinics within 5 years of diagnosis (age range, 30-70 years) examined cross-sectionally clinically and for GAD antibodies (GADA) and antibodies to insulinoma-associated antigen-2 (IA-2A) and zinc-transporter 8 (ZnT8A).

Results: Of 6,156 patients, 541 (8.8%) had GADA and only 57 (0.9%) IA-2A or ZnT8A alone. More autoantibody-positive than autoantibody-negative patients were younger, leaner, on insulin (49.5 vs. 13.2%), and female (P < 0.0001 for each), though LADA patients (9.7% of total) did not show categorically distinct clinical features from autoantibody-negative type 2 diabetes. Similarly, more GADA patients with high (>200 World Health Organization IU) (n = 403) compared with low (n = 138) titer were female, lean, and insulin treated (54.6 vs. 39.7%) (P < 0.02 for each). Autoantibody-positive patients usually had GADA (541 of 598; 90.5%) and had LADA more often than type 1 autoimmune diabetes (odds ratio 3.3).

Conclusions: Adult-onset autoimmune diabetes emerges as a prevalent form of autoimmune diabetes. Our results indicate that adult-onset autoimmune diabetes in Europe encompasses type 1 diabetes and LADA in the same broad clinical and autoantibody-positive spectrum. At diagnosis, patients with adult-onset autoimmune diabetes are usually non-insulin requiring and clinically indistinguishable from patients with type 2 diabetes, though they tend to be younger and leaner. Only with screening for autoantibodies, especially GADA, can they be identified with certainty.

Figures

Figure 1
Figure 1
Venn diagram of numbers of patients with GADA, IA-2A, or ZnT8A; n = 598 of 6,156 (9.8%). Of the autoantibody-positive samples, GADA was identified in 90% of the samples when an autoantibody was detected, with IA-2A and ZnT8A accounting for the remaining 10% of the autoantibodies detected. GADA, n = 541 (8.8%); IA-2A, n = 144 (2.3%); and ZnT8A, n = 110 (1.8%).

References

    1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010;464:1293–1300
    1. Leslie RD, Williams R, Pozzilli P. Clinical review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006;91:1654–1659
    1. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999;48:150–157
    1. Hosszúfalusi N, Vatay A, Rajczy K, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003;26:452–457
    1. Buzzetti R, Di Pietro S, Giaccari A, et al. Non Insulin Requiring Autoimmune Diabetes Study Group High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007;30:932–938
    1. Zinman B, Kahn SE, Haffner SM, O’Neill MC, Heise MA, Freed MI, ADOPT Study Group Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004;53:3193–3200
    1. Turner R, Stratton I, Horton V, et al. UK Prospective Diabetes Study Group UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997;350:1288–1293
    1. Rosário PW, Reis JS, Amim R, et al. Comparison of clinical and laboratory characteristics between adult-onset type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care 2005;28:1803–1804
    1. Leslie RD, Kolb H, Schloot NC, et al. Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev 2008;24:511–519
    1. Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005;54(Suppl. 2):S62–S67
    1. Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005;48:2206–2212
    1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197
    1. Hawa MI, Fava D, Medici F, et al. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care 2000;23:228–233
    1. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007;104:17040–17045
    1. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003;52:1128–1136
    1. Brophy S, Yderstraede K, Mauricio D, et al. Action LADA Group Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 2008;31:439–441
    1. Davies H, Brophy S, Fielding A, et al. Latent autoimmune diabetes in adults (LADA) in South Wales: incidence and characterization. Diabet Med 2008;25:1354–1357
    1. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia 2001;44:3–15
    1. Petrone A, Suraci C, Capizzi M, et al. NIRAD Study Group The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3. Diabetes Care 2008;31:534–538
    1. Hawa MI, Thivolet C, Mauricio D, et al. Action LADA Group Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care 2009;32:160–164
    1. Lorenzen T, Pociot F, Hougaard P, Nerup J. Long-term risk of IDDM in first-degree relatives of patients with IDDM. Diabetologia 1994;37:321–327

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅